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Background and aim: To estimate the prevalence of cardiovascular (CV) disease and CV risk factors
among Polish patients.
Methods: A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the 4th
quarter of 2015 and 1st and 2nd quarters of 2016; 438 primary care physicians enrolled 13,724 adult
patients that sought medical care in primary health care practices.
Results: Nearly 19% of men and approximately 12% of women had cardiovascular disease (CVD). Over 60%
of the recruited patients had hypertension (HTN), >80% had dyslipidaemia and <15% of patients were
diagnosed with diabetes (DM). All of these disorders were more frequent in men. In 80% of patients the
waist circumference exceed norm for the European population. Less than half of the patients were
current smokers or had smoked in the past. Patients with CVD had significantly higher blood pressure
and glucose levels but lower low density lipoprotein-cholesterol level.
Conclusions: The prevalence of CVD and CV risk factors among patients in Poland is high. CVD is more




s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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CVD in the primary health care population.
© 2021 Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Cardiovascular disease (CVD) is currently one of the leading
cause of mortality in the European Union (EU), where it causes
around 800,000 deaths in men and 1 million deaths in women
annually [1]. In 2015, within the EU, almost 49 million people were
living with CVD. A higher CVD mortality burden is found in Central
and Eastern European (CEE) countries compared with Northern,
Southern and Western European states. In Greece in 2015, the age-
standardised prevalence rate of CVD per 100,000 in women and
men was 4052 and 5,189, respectively. During the same year, these
rates in Poland were 6709 and 8830 [2,3].
Well-known, modifiable cardiovascular (CV) risk factors include
elevated blood pressure (BP), hypercholesterolaemia, diabetes
mellitus, obesity, low activity levels, poor diet and smoking. The
prevalence of these, as well as the prevalence of CVD itself, aremore
common in the CEE than in Western Europe. In Poland, as in other
countries of the CEE region (e.g. Slovakia and the Czech Republic),
the prevalence of CV risk factors (except smoking) is increasing
continuously [2].
There are estimates on the prevalence of CV risk factors in
Poland, conducted at the beginning of previous decade on small
segments of the population that only partially include primary care
patients (e.g. NATPOL 2011 [4,5], WOBASZ II (2013/14) [5,6]).
However, there are no current estimates on the prevalence of CV
risk factors among patients solely in the primary care setting. LIP-
IDOGRAM [7,8] is a large cross-sectional study that was initiated in
2010, with a continuation of data collection in 2015 and 2016.
Improved control and reducing the prevalence of CV risk factors
is one of the principal goals of primary care medicine. Effective
primary care and preventative medicine can modify premature
death, myocardial infarction (MI), ischemic stroke, and need for
revascularization among patients at risk. Physicians providing pri-
mary health care identify and treat patients with CV risk factors and
play prominent roles in implementing CVD prevention strategies
within the communities they serve. According to the guidelines of
the European Society of Cardiology (ESC), general practitioners
(GPs) should provide CV risk factor evaluation, deliver intervention
for high-risk patients, and educate patients. GPs should also detect
CVD at an early stage, treat patients, and cooperate with other
health professionals so as to optimize health care delivery [9,10].
The preventable mortality rate in Poland decreased by about
10% between 2011 and 2016. However, it continues to be higher
than in most EU Member States [11]. Knowledge of CV risk factor
prevalence in the Polish population is necessary in order to
implement a broad, effective strategy aimed at reducing mortality,
morbidity, and disability resulting from CVD.2. Aim
The aim of this study is to determine: (1) the prevalence of CV
disease, and, (2) ascertain CV risk factor prevalence, including hy-
pertension (HTN), impairments in glycemic control, and cholesterol
fraction levels in men and women treated in primary care in
Poland.163. Methodology
3.1. Design
A nationwide cross-sectional study, LIPIDOGRAM2015, was
carried out in Poland in the 4th quarter of 2015 and 1st and 2nd
quarters of 2016.
3.2. Setting
A group of 700 physicians-investigators working in public or
private Primary Health Care Practices were randomly selected by
principal investigator from theMedical DataManagement database
using computer software. The database includes national repre-
sentation of primary care doctors. The group of 700 physicians-
investigators was selected in a manner proportional to the num-
ber of inhabitants in a given administrative region (so called voi-
vodeship). It was assumed that each physician-investigator will
include at least 30 patients remaining under his medical care in the
LIPIDOGRAM 2015 study. Due to the statistical correctness of the
results, the number of patients included in the survey in the
smallest Polish voivodeship (Lubuskie voivodeship - 2.64% of the
population of Poland), should not be lower than 550 people. A total
of 438 physicians in 398 practices in 16 major administrative re-
gions were recruited.
3.3. Participants
Between October 2015 and June 2016, a total of 438 primary care
physicians actively enrolled 13,724 patients. Inclusion criteriawere:
(1) age above 18 years, (2) being under the care of the given-
physician-investigator, (3) soughing care for any medical reason
in primary health care practices, (4) give voluntary written consent
to participate in the study. The patient was excluded if he (1) was
legally deprived of the ability to make decisions or (2) planned to
change his place of residence. 262 (37,4%) physicians refused to
participate, the main reason reported was lack of time. Each
physician-investigator consecutively recruited into this study at
least 30 adults attending their primary care practices. Prior to data
collection, each physician-investigator undertook individual
training related to the study procedure and methodology as
described in the LIPIDOGRAM2015 study design [12]. A flow-chart
of patients remarking the number of eligible participants, the
number of selected and excluded patients, is presented as
Supplementary material 1.
3.4. Measurements
For each patient recruited for the study, a 28 item questionnaire
was collected that gathered data on chronic diseases and their
treatment, lifestyle (diet, physical activity, smoking status), and
family history of CVD (altogether 24 questions). The questionnaire
also recorded demographic data: age, sex, place of residence and
level of education (altogether 4 questions). To prevent missing data
only critical data elements were collected to minimize burden and
focus on data routinely collected. The questionnaire was tested in a
group of 10 primary care physicians who did not submit comments
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checked by comparing the questionnaire with other similar tools
used in Poland (the English translation of the questionnaire is
presented in the LIPIDOGRAM2015 study design [12].
In all patients, anthropometric measurements were made
(height, body weight, waist circumference and hip circumference).
Height and weight measurements were carried out without heavy
clothing and shoes. Waist circumference was measured over the
unclothed abdomen at a level of the midpoint between the lower
margin of the ribs and the anterior superior iliac crest spine. Hip
circumference was measured at the level of the greater trochanters.
On the same day, measurements of BP and fasting glucose and lipid
profile were taken. Patients were fasting for at least 12 h prior to the
blood sample collection.
The collected blood samples were transferred in cooled con-
tainers to the central laboratory (Silesian Analytical Laboratories in
Katowice, Poland). Measurements of total cholesterol, triglycerides,
high-density lipoprotein cholesterol (HDL-C) and low-density li-
poprotein cholesterol (LDL-C) (both by direct immunological
measurement) were made using the same methodology and the
same SIEMENS ADVIA 1800 analyser and SIEMENS reagents, within
12 h of drawing. The reference intervals of laboratory parameters
were based on ESC guidelines of 2011 [13]. Fasting glycaemia was
measured using BIONIME glucometers and RIGHTEST strip tests,
which indicated an acceptable accuracy and precision [14]. On the
same day, office BP measurements were performed with standard
sphygmomanometers according to 2013 ESC/ESH Guidelines for the
management of arterial HTN [15].
3.5. Definitions and classification
HTN, DM and dyslipidaemia were defined in accordance with
current guidelines (presented also in Supplementary material 2)
[13,16,17].
Patients were defined as with HTN when: (1) HTN was prior
diagnosed; or (2) patient used at least one hypotensivemedication;
or (3) office SBP was 140 mmHg and/or office DBP was
90 mmHg. Patients were defined as with dyslipidaemia when: (1)
dyslipidaemia was prior diagnosed; or (2) patient used at least one
lipid-lowering medication; or (3) LDL-C level was 115 mg/dl and/
or TG level was 150 mg/dl. Patients were defined as with DM
when: (1) DM was prior diagnosed; or (2) patient used at least one
hypoglycaemic medication.
Present CVD was defined as CVD confirmed prior to the onset of
the LIPIDOGRAM study by invasive or non-invasive testing, and
incuded: coronary heart disease (previous angina with or without
acute coronary syndrome), previous myocardial infarction, atrial
fibrillation or ischemic stroke [13].
WHO classification of obesity, based on the Body Mass Index
(BMI), was used [18]. Normal waist circumference (<80 cm in
women and <94 cm in men) was established according to the In-
ternational Diabetes Federation (IDF) recommendations [19].
Abdominal obesity was defined as the waist-hip ratio (WHR)  1
for men, and WHR  0.85 for women. Smokers were defined as
patients who smoked at least one cigarette daily. Patients were
defined as being treated for HTN, DM or dyslipidaemia when they
use at least one hypotensive or hypoglycaemic or lipid-lowering
medication, respectively.
3.6. Statistical analysis
Frequency rates are presented for variables measured on a
nominal or ordinal scale. The categorical variables were compared
between the patients with and without CVD using the Pearson’s
chi-square and continuous variables were compared using the17Student t-test or the U Mann-Whitney test as appropriate. Statis-
tical significance was determined when p is < 0.05 and p values
were unadjusted for multiple comparisons. All statistical analyses
were conducted using the STATISTICA programme, version 13.
3.7. Ethical issue
All individuals signed an informed consent to participate in the
study and gave their permission to use anonymous questionnaire
data, the results of their laboratory tests and secured biologic ma-
terial for the purpose of statistical and scientific studies.The LIP-
IDOGRAM2015 study received a positive opinion from the
Bioethical Commission of the District Medical Chamber in Często-
chowa on December 02, 2015 (No K.B.Cz.-0018/2015) and conforms
to the principles outlined in the Declaration of Helsinki.
4. Results
4.1. Population characteristics
The LIPIDOGRAM2015 study involved 13,724 patients (8690
women and 5034 men). The average age was 56.4 years (56.2 in
men, 56.4 in women). Demographic characteristics of enrolled
patients including the division into thosewith and without CVD are
presented in Table 1.
CVD was present in 1965 (15.4%) of patients and was more
common in men (19%) than in women (11.6%). Coronary heart
disease was present in 1787 (13%) of patients (10.4% of women and
17.4% of men). MI was present in 625 (4,6%) patients (2.2% of
women and 8.6% of men), ischemic stroke in 268 (2%) of patients
(1.6% of women and 2.5% of men) and hemorrhagic stroke in 31
(0.2%) of patients (0.2% of women and 0.3% of men).
Over 60% of participants had HTN (58.4% of women and 69.6% of
men). Mean office BP values in patients treated for HTN were 139/
83 mmHg, in people not treated for HTN mean BP values were 126/
78 mmHg. Details regarding office systolic and diastolic BP are
presented in Table 2.
DM was present in 11.8% of women and 16.3% of men. Mean
glucose values in patients treated for DM were 137 mg/dl and in
non-treated subjects, 99 mg/dl (Table 2).
Dyslipidaemia was present in 82.4% of women and 88.7% of
men. In people treated for this condition, mean total cholesterol
values were 192 mg/dl and mean LDL cholesterol values were
118 mg/dl. In patients without treatment, mean total cholesterol
values were 208 mg/dl and mean LDL cholesterol values were
134 mg/dl (Table 3).
In the study population during the relevant period, less than 17%
of patients smoked cigarettes but almost 1/3 reported that they had
smoked in the past. Underweight was found in less than 1% of
patients, and 25% of respondents had normal body weight. Over-
weight and obesity were present in almost 75% of participants
(overweight in 39.5%, first-degree obesity in 24.7%, a second-degree
in 7.6%, and third-degree in 2.5%). Waist circumference exceeding
the norm was found in almost 80% of patients. Abdominal obesity
was found in almost 45% of the subjects. The prevalence of CVD risk
factors is shown in Fig. 1.
4.2. The prevalence of CV risk factors in patients with CVD and
without CVD
In patients without CVD, HTN occurred in 58.2%. In the sub-
population of patients with CVD, HTNwas present in 88.5% (Fig.1a).
Mean BP values, as well as the differences in groups with and
without CVD, are presented in Table 2.
DMwas found in 10.6% of patients without CVD. Among patients
Table 1
Demographic characteristics of patients with CVD and without CVD in the LIPIDOGRAM2015 study.
All Men Women
total CVD (þ) CVD () total CVD (þ) CVD () total CVD (þ) CVD ()












age X± SD (years) 56 ± 14 67 ± 9.5 54 ± 13 56 ± 14 66 ± 9 54 ± 14 56 ± 14 68 ± 10 55 ± 13
p < 0.01 p < 0.01 p < 0.01

























p ¼ 0.71 p ¼ 0.22 p ¼ 0.06

















































p < 0.01 p < 0.01 p < 0.01
CVD e cardiovascular disease, SD e standard deviation.
Table 2
Level of BP and glucose in patients with CVD and without CVD in the LIPIDOGRAM2015 study.
All Men Women
total CVD (þ) CVD () Total CVD (þ) CVD () total CVD (þ) CVD ()
Total (n) 13724 1965 11759 5034 956 4078 8690 1009 7681
SBP
X±SD (mmHg) 132 ± 18 137 ± 19 131 ± 18 135 ± 18 137 ± 19 135 ± 17 130 ± 19 138 ± 19 129 ± 18
p < 0.01 p < 0.01 p < 0.01
DBP
X±SD (mmHg) 80 ± 11 81 ± 11 80 ± 11 83 ± 11 82 ± 11 83 ± 10 79 ± 10 81 ± 11 79 ± 10
p < 0.01 p < 0.01 p < 0.01
Treated for HTN (n) 6515 1592 4923 2516 768 1748 3999 824 3175
SBP
X±SD (mmHg) 139 ± 18 140 ± 19 139 ± 18 140 ± 18 139 ± 19 141 ± 18 138 ± 18 140 ± 19 138 ± 18
p ¼ 0.04 p ¼ 0.11 p < 0.01
DBP
X±SD (mmHg) 83 ± 11 82 ± 11 83 ± 11 84 ± 11 83 ± 11 85 ± 11 82 ± 10 81 ± 11 82 ± 10
p ¼ 0.01 p ¼ 0.00 p ¼ 0.20
Non-treated for HTN (n) 7209 373 6836 2518 188 2330 4691 185 4506
SBP
X±SD (mmHg) 126 ± 16 129 ± 17 126 ± 16 131 ± 16 130 ± 18 131 ± 16 124 ± 16 129 ± 17 123 ± 16
p < 0.01 p ¼ 0.47 p < 0.01
DBP
X±SD (mmHg) 78 ± 10 78 ± 10 78 ± 10 81 ± 10 79 ± 11 81 ± 10 77 ± 10 78 ± 10 77 ± 10
p ¼ 0.98 p < 0.01 p ¼ 0.19
glycaemia X± SD (mg/dl) 103 ± 25 113 ± 32 102 ± 23 106 ± 27 113 ± 32 104 ± 26 102 ± 23 112 ± 32 101 ± 22
p < 0.01 p < 0.01 p < 0.01
Treated for DM (n) 1728 570 1158 770 290 480 958 280 678
glycaemia X± SD (mg/dl) 137 ± 42 138 ± 42 137 ± 42 139 ± 42 139 ± 40 139 ± 44 136 ± 42 137 ± 43 135 ± 41
p ¼ 0.54 p ¼ 0.91 p ¼ 0.91
Non-treated for DM (n) 11996 1395 10601 4264 666 3598 7732 7003 729
glycaemia X± SD (mg/dl) 99 ± 16 102 ± 19 98 ± 16 100 ± 18 102 ± 19 99 ± 17 98 ± 15 97 ± 15 102 ± 19
p < 0.01 p < 0.01 p < 0.01
CVD e cardiovascular disease, DBP e diastolic blood pressure, SBP e systolic blood pressure, HTN e hypertension, DM - diabetes, SD e standard deviation.
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Mean values of glycaemia and statistical significance of differences
in the groups with and without CVD are presented in Table 2.
Dyslipidaemia was detected in 83.7% of people without CVD.
Among patients with CVD, 90.8% had dyslipidaemia (Fig. 1a). Mean
values of cholesterol fraction, as well as the statistical significance
of differences in groups without and with CVD, are presented in
Table 3.18In patients without CVD, overweight was found in 39.9% and
obesity in 32.8%. Excess waist circumference (80 cm in women
and 94 cm in men) was detected in 77.4%. Abdominal obesity
(WHR  1 for men and 0.85 for women) was found in 43.1%
(Fig. 1b).
In patients with diagnosed CVD, overweight was present in
36.6% and obesity in 47.3%. Excess waist circumference (80 cm in
women and 94 cm in men) was detected in 88.9%. Abdominal
Table 3
Lipids profile in patients with CVD and without CVD in the LIPIDOGRAM2015 study.
All Men Women
total CVD (þ) CVD () total CVD (þ) CVD () total CVD (þ) CVD ()
Total (n) 13724 1965 11759 5034 956 4078 8690 1009 7681
TC X±SD (mg/dl) 202 ± 44 184 ± 45 206 ± 43 198 ± 45 175 ± 41 203 ± 44 205 ± 44 192 ± 47 207 ± 43
p < 0.01 p < 0.01 p < 0.01
HDL-C X±SD (mg/dl) 55 ± 15 50 ± 14 56 ± 15 48 ± 13 45 ± 12 49 ± 13 59 ± 15 55 ± 14 59 ± 15
p < 0.01 p < 0.01 p < 0.01
LDL-C X±SD (mg/dl) 129 ± 41 114 ± 41 131 ± 40 127 ± 40 109 ± 38 132 ± 39 129 ± 41 118 ± 43 131 ± 40
p < 0.01 p < 0.01 p < 0.01
non-HDL-C X±SD (mg/dl) 148 ± 42 134 ± 42 150 ± 42 150 ± 44 130 ± 39 154 ± 43 146 ± 41 137 ± 44 147 ± 41
p < 0.01 p < 0.01 p < 0.01
TG X±SD (mg/dl) 148 ± 118 153 ± 104 147 ± 121 172 ± 153 160 ± 127 174 ± 158 135 ± 90 146 ± 76 133 ± 92
p ¼ 0.03 p ¼ 0.01 p < 0.01
Treated for dyslipidaemia (n) 4703 1296 3407 1899 651 1248 2804 645 2159
TC X±SD (mg/dl) 192 ± 47 178 ± 45 197 ± 46 186 ± 46 171 ± 40 194 ± 47 196 ± 47 185 ± 48 199 ± 46
p < 0.01 p < 0.01 p < 0.01
HDL-C X±SD (mg/dl) 52 ± 15 49 ± 14 54 ± 15 47 ± 13 44 ± 12 48 ± 14 56 ± 15 54 ± 14 57 ± 15
p < 0.01 p < 0.01 p < 0.01
LDL-C X±SD (mg/dl) 118 ± 42 108 ± 40 121 ± 42 115 ± 39 105 ± 36 120 ± 40 120 ± 44 110 ± 43 122 ± 43
p < 0.01 p < 0.01 p < 0.01
non-HDL-C X±SD (mg/dl) 139 ± 44 129 ± 42 143 ± 45 139 ± 45 127 ± 38 146 ± 47 140 ± 44 131 ± 45 142 ± 44
p < 0.01 p < 0.01 p < 0.01
TG X±SD (mg/dl) 164 ± 142 158 ± 115 167 ± 150 183 ± 174 166 ± 140 192 ± 189 151 ± 112 150 ± 81 152 ± 120
p ¼ 0.03 p < 0.01 p ¼ 0.57
Non-treated for dyslipidaemia (n) 9021 669 8352 3135 305 2830 5886 364 5522
TC X±SD (mg/dl) 208 ± 42 195 ± 44 209 ± 42 205 ± 43 183 ± 43 207 ± 42 210 ± 41 205 ± 42 210 ± 41
p < 0.01 p < 0.01 p ¼ 0.02
HDL-C X±SD (mg/dl) 56 ± 15 52 ± 13 57 ± 15 49 ± 13 46 ± 11 49 ± 13 60 ± 15 57 ± 13 60 ± 15
p < 0.01 p < 0.01 p < 0.01
LDL-C X±SD (mg/dl) 134 ± 39 125 ± 40 135 ± 38 135 ± 38 119 ± 40 137 ± 38 134 ± 39 131 ± 39 134 ± 39
p < 0.01 p < 0.01 p ¼ 0.11
non-HDL-C X±SD (mg/dl) 152 ± 40 144 ± 40 152 ± 40 156 ± 42 138 ± 40 158 ± 41 150 ± 40 148 ± 40 150 ± 40
p < 0.01 p < 0.01 p ¼ 0.56
TG X±SD (mg/dl) 140 ± 103 144 ± 80 140 ± 105 165 ± 137 151 ± 92 166 ± 141 127 ± 77 139 ± 68 126 ± 77
p ¼ 0.14 p ¼ 0.01 p < 0.01
CVD e cardiovascular disease, TC e total cholesterol, HDL-C e high-density lipoprotein cholesterol, LDL-C e low-density lipoprotein cholesterol, TG - triglycerides, SD e
standard deviation.
To receive values in mmol/l: (1) for TC, HDL-C, and LDL-C please divide the value in mg/dl by 38.67; (2) for TG please divide the value in mg/dl by 88.57.
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17.4% patients without CVDwere current smokers and 27.7% had
smoked in the past. Among patients with diagnosed CVD, 13.0%
were current smokers and 39.1% had smoked in the past (Fig. 1c).
The number of CV risk factors was higher in both female and
male patients with CVD in comparison with those without it
(p < 0.01). All participating in the study women had a significantly
lower number of CV risk factors than men (p < 0.01) (Fig. 2a). The
proportion of patients with multiple risk factors increased sub-
stantially with age e the correlation coefficient Gamma is 0.31 for
the entire study population (0.39 for women, 0.20 for men).
However, this phenomenon did not apply to the oldest age groups
(Fig. 2b).Fig. 2.5. Discussion
5.1. Main findings
In the population of men and women seeking medical care in
primary health care practices in Poland in 2015 and 2016, nearly
19% of men and approximately 12% of women had CVD. Over 60% of
the recruited patients had HTN, > 80% had dyslipidaemia and <15%
of patients were previously diagnosed with DM. All of these dis-
orders were more frequent in men. Overweight and obesity were
present in more than three-quarters of patients with four-fifths of
them exceeding the waist circumference norm for the European19population. Slightly less than half of the patients were current
smokers or had smoked in the past. Patients with CVD had signif-
icantly higher BP and glucose levels but lower LDL-C level. In pa-
tients with CVD, HTN and dyslipidaemiawere twice as frequent and
DM three times more so than in patients without it.5.2. Comparison with other studies
There are substantial differences in the prevalence of CVD and
CV risk factors between European countries. This fact is confirmed
by recent studies on the prevalence of metabolic risk factors [20],
HTN [21,22] and obesity [23]. A higher CVD mortality burden is
found in CEE countries compared to that in Northern, Southern and
Western European countries [24].
In NATPOL2011, which was conducted in Poland in 2011 on a
representative sample of 2417 individuals from the general popu-
lation aged from 18 to 79 years, HTNwas found in 36.8% of men and
29.4% of women. Hypercholesterolaemia was present in 61.1%
participants, DM occurred in 7.0% of men and 6.4% of women and
obesity e 23.6% and 19.7%, respectively [25].
In another study conducted in Poland in 2013e2014, WOBASZ II,
hypertension occurred in 46.2% of men and 40.4% of women [26]
and hypercholesterolaemiawas found in 70.3% of men and in 64.3%
of women [27]. Prevalence of obesity was 24.4% inmen and 25.0% in
women and the prevalence of overweight was 43.2% and 30.5%,
respectively. Excess waist circumference (94 cm in men or
Fig. 1. Prevalence of cardiovascular risk factors among patients with CVD and without CVD in the LIPIDOGRAM2015 study. Fig. 1a. Prevalence of HTN, DM and dyslipidaemia among
patients with CVD and without CVD. Fig. 1b. Prevalence of weight disorders among patients with CVD and without CVD. Fig. 1c. Smoking status of patients with CVD and without
CVD. CVD - cardiovascular disease.
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[28]. The prevalence of regular tobacco smoking was 29.9% among
men and 20.5% among women [29]. However, the population in
WOBASZ II study was older (above 20 years old). The participation
rates for WOBASZ and WOBASZ II was around 75% and 47%,
respectively. Some results were based on a survey questionnaire
only and DM prevalence was not taken into consideration.20In the LIPIDOGRAM2004 and LIPIDOGRAM2006 studies, the
prevalence rate of overweight and obesity among adult patients
remaining under the care of family physicians in Poland were
assessed. Approximately 75% of the patients included in studies had
BMI >25 kg/m2. The overweight rate was higher among men than
women (48.0% vs 39.2% in 2004, and 47.4% vs 39.7% in 2006).
Obesity was present in >30% of participants - in 2004 32.8% in men
Fig. 2. Number of risk factors among patients participating in the LIPIDOGRAM2015 study. Fig. 2a. Number of risk factors among patients with CVD and without CVD.Fig. 2b.
Number of risk factors among patients in different age groups. Risk factors included in the analysis: hypertension, dyslipidaemia, diabetes mellitus, current cigarette smoking,
obesity (BMI 25). CVD - cardiovascular disease.
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LIPIDOGRAM 2015, the obesity rate was even higher (38.2% in men
and 32.9% in women) [7,30,31].
The results of the LIPIDOGRAM2015 study are similar to other
studies from Central and Eastern Europe. In a project carried out in
2014e2016 on 1051 patients from the general population in Prague,
Czech Republic, the prevalence of hypercholesterolaemia and
hyperglycaemiawere 49% and 12.8% inwomen and 52.9% and 18.9%
in men, respectively. Obesity and overweight were present in 16.3%
and 26.7% of women and 20.3% and 48.8% of men. Excess waist
circumference was diagnosed in 56.1% of women and 57% of men.21However, the population in this study was limited to one city only
and other CV risk factors, including HTN, were not taken into
consideration [32]. In research conducted in 2007 on 1111 patients
age 20e65 years from the general population in Tallinn, Estonia,
HTN occurred in 26.1% of women and 36.8% of men. The prevalence
of overweight and excess waist circumference was 48.3% and 44.5%
in women and 62.6% and 48.5% in men, respectively. Hyper-
cholesterolaemia and type 2 DM were present in 62% and 2.7% of
women and 70.7% and 4% of men. In 2007, 20.5% of women and
36.1% of men were current smokers. However, the population in
this study was also limited to one city only and other CV risk factors
J.J. Jozwiak, K. Studzinski, T. Tomasik et al. Atherosclerosis Supplements 42 (2020) e15ee24were not taken into consideration [33]. The higher prevalence of CV
risk factors that was shown in our study may be caused by the
composition of the study population as these were patients who
sought medical assistance in primary health care practices and
were not from the general population.
5.3. Strengths and limitations
To the best of our knowledge, this is the largest epidemiological
study concerning CVD and CV risk factors representative of the
regional distribution of residents in Poland in the last 5 years. This
is the only study in Poland specifically aimed at the primary care
patient population who seek medical care. Data uncovering the
burden of CVD risk factors in a primary healthcare setting in Poland
which may be of importance for other regions. Moreover, it is a
hands-on study in which data has been collected in detail and is
relevant for primary and secondary prevention. Other strengths of
our studywere that laboratory tests of lipids levels were carried out
in the central laboratory and the fact that all physician-
investigators underwent training.
There are also some obvious limitations. The study enrolled
patients who seek medical assistance in primary health care prac-
tices and is not representative of the general Polish population
since around 10% of patients in Poland are not entitled (due to lack
of insurance or not choosing their GP) to use this service. The study
period did not include the summer months, which may influence
the results. A relatively large proportion of primary care physicians
refused to participate in the study. Moreover, patients in individual
practices were not recruited by a randomization process. Physicians
enrolled patients consecutively. No follow-up was performed,
which is one of the limitations often found in observational studies.
Additionally, the glucose level was measured by a glucometer, not
by the most precise method, hence these measurements were not
taken into account for defining of glucose impairment.
5.4. Interpretation and implication
The study provides relevant, current and precise data on the
prevalence of CVD and CV risk factors in a representative sample of
patients attending primary healthcare for various reasons in
Poland.
The results of the study draw attention to the fact that in Poland
men less often than women use primary health care (1:3). The
larger female population enrolled in the study is due to the fact that
women report to primary care more often than men. A similar
trend was observed in previous LIPIDOGRAM studies [7,8,30,31].
Because of that, it is also worth considering using female partners
as a channel to reach menwho do not use preventive and screening
tests in primary healthcare.
The results of our study are important for family doctors. They
confirm the well-known fact that CVD and CV risk factors occur
frequently in the population covered by family doctor care, and also
provide quantitative data in this field. Physicians should aware of
the essential findings of this study. Firstly, CVD and its major risk
factors are more common in men than women. Secondly, risk fac-
tors are more common in patients with CVD than without them.
Both of these facts should be taken into account when planning
activities in primary and secondary prevention. The results of our
study can also be helpful for family doctors in the planning of
continuous education and should be taken into account in the ac-
tivities for the development of practices and quality improvement.
The results are also important for cardiologists. They indicate
the possibility of taking action in primary health care in the field of
primary and secondary CVD prevention and the need for close
cooperation between cardiologists and family doctors in the22diagnosis and treatment of patients with CVD.
Study results provide public health specialists with accurate
data on the prevalence of risk factors and CVD. This data should be
taken into account when planning policies, allocating resources and
financing CVD prevention. This is particularly important, because in
2016 preventable mortality in Poland was 218 per 100,000 popu-
lation and was significantly higher than the EU average of 161.
Moreover, the central national audit carried out in Poland in the
years 2012e2015 showed that the financing of preventive mea-
sures was insufficient and in addition, the funds were inappropri-
ately allocated [11].
Researchers are able to make comparisons with previous LIP-
IDOGRAM studies and follow trends in the prevalence of CVD and
CV risk factors in the population of patients attending primary
healthcare in Poland. It also seems beneficial to continue research
on primary healthcare patients in Poland in the future and to start
similar research in the other countries of Central and Eastern
Europe.6. Conclusions
The prevalence of CVD and CV risk factors among patients
attending primary healthcare in Poland is high, but it seems not to
differ from the frequency in other countries of Central and Eastern
Europe. The most common CV risk factors are excess waist
circumference, dyslipidaemia and HTN. Among patients in the
primary care setting seeking medical care in Poland, CVD is more
common in men than in women. Family physicians working in
primary health care, as well as health authorities at all levels from
local to national, should conduct activities to prevent, diagnose
early and treat CVD in the primary health care population.Authors
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